New ESMO Clinical Practice Guideline on Lymphomas
European Society for Medical Oncology (ESMO) shared a post on X:
“New ESMO Clinical Practice Guideline on Lymphomas: evidence-based recommendations for all major lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.”
Lizzy Smyth, Clinical Lead at Oxford Clinical Trials Office, shared this post, adding:
“MASSIVE congrats to the ESMO lymphoma guidelines authors for squeezing EVERY major lymphoma subtype into this MEGA guideline.
This is a great resource for any oncologist treating lymphoma.”
The ESMO Clinical Practice Guideline on Lymphomas provides concise, expert recommendations for diagnosing, treating, and monitoring various lymphoma subtypes, including DLBCL, FL, HL, MCL, MZL, PCNSL, and PTCL.
It includes clear treatment algorithms and covers key areas such as staging, risk assessment, and management of both primary and relapsed disease. Developed by a multidisciplinary team, the guideline supports consistent, high-quality care across Europe.
More posts featuring ESMO on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023